Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Market Access
  • Where Gross-to-net Pressure Actually Lives After Launch
  • Market Access

Where Gross-to-net Pressure Actually Lives After Launch

Drug Channels

Today's guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Read full story

pharminent May 1, 2026 (Last updated: May 1, 2026)

Drug Channels

Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Read full story

Post navigation

Previous: Two biotechs raise a combined $556M in latest spurt of IPOs
Next: BMS brings the buzz around late-stage readouts amid a so-so Q1

Related Stories

  • Market Access

How cost and perception could reshape the GLP-1 market

pharminent August 21, 2026
  • Market Access

D.C. Circuit Affirms HHS Authority Over 340B Rebate Models

pharminent July 24, 2026
  • Market Access

NICE aims to cut funding for Amgen lung cancer drug Lumykras

pharminent July 9, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.